Clinical Trial Update: A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of Fovista in combination with Avastin or Eylea for age-related macular degeneration was terminated with results posted in Sep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Avastin (bevacizumab)
• EYLEA (Aflibercept)
• Fovista (E10030)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Age-Related Macular Degeneration | Phase 3 | Status: TERMINATED | Results posted: 2020-09-30